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Abstract 
 In the United States, sepsis afflicts nearly one in three ICU patients, is associated with 
monumental healthcare costs, and is among the leading causes of death. The burden of sepsis is 
felt globally, and efforts are underway to discover an effective adjunctive therapy. Vitamin C is a 
novel treatment showing promising early evidence. A a , a  C    c b a  
therapy with hydrocortisone and thiamine has been postulated. These components are thought to 
work congruently to attenuate the pathophysiologic process of sepsis.  
 To answer whether vitamin C improves septic patient outcomes, a variety of methods 
were used to obtain information. Primarily, the electronic database PubMed was utilized to 
perform a literature search. Most sources had full-text versions available and those that did not 
we  b a   A b  U  b a  a  . F a ,   
were conducted with practicing c a  a  hysician assistants that have experience 
managing sepsis. 
 Standard care protocols, definitions and recommendations implemented by the Surviving 
Sepsis Campaign and the Sepsis-3 Task Force have improved septic patient outcomes 
substantially, however, sepsis continues to burden patients and health systems globally. Offering 
affordability and accessibility, vitamin C may be the adjunct sepsis treatment the medical 
community has been searching for. Overall, the available evidence suggests vitamin C is safe, 
improves mortality and reduces hospital resource consumption, among other various measured 
outcomes. Many clinical trials are currently in progress or awaiting publishing. Results from 
these studies will further define the efficacy of vitamin C alone and in combination with 
hydrocortisone and thiamine.  
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Introduction 
 Hospital beds within intensive care units (ICUs) around the world are occupied by the 
critically ill fighting for their lives. Of these patients, approximately one in three are admitted 
with sepsis, or will develop nosocomial sepsis during their stay in the ICU.1 Sepsis, defined as 
- a  a  c  ca  b  a a     c , 
develops in 750,000 patients in the United States alone.2 This disease process accounts for six 
million deaths worldwide each year, it ranks as the third leading cause of death in the United 
States, and is a contender for most expensive cause of hospitalization.3,4 The sequela of sepsis go 
beyond short-term mortality. Among survivors, as many as 50% go on to develop post-sepsis 
syndrome, characterized by an increased risk of death along with physical, psychological, and 
neurological manifestations.5,6 Sepsis also carries rehospitalization rates of 40% at 90 days for 
various reasons such as reinfection or exacerbation of an underlying condition.6 The Surviving 
Sepsis Campaign (SSC) is a multidisciplinary group of professionals with an initiative aimed at 
providing standardized protocols in the management of septic patients to reduce worldwide 
sepsis morbidity and mortality. These standardized protocols were last updated in 2016 and 
include initial resuscitation, sepsis screening and diagnosis, antimicrobial therapy, and 
supportive care interventions.2 Although these standards of care have improved patient outcomes, 
sepsis continues to be a leading cause of mortality in ICUs and a major burden economically.7 
Given the scope of the issue, research centered around methods to identify septic patients and 
prospective therapies and interventions is ongoing. Research has proven difficult, as there have 
been more than 100 phase II and III clinical trials utilizing pharmacologic agents acting on 
specific molecular targets that have failed to improve clinical outcomes in septic patients.5,8 
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One such prospective intervention garnering promise is vitamin C. Also known as 
ascorbic acid, vitamin C has been implicated in providing immune benefits to critically ill 
patients, and interestingly, a multitude of studies have shown vitamin C levels to be significantly 
depleted in said patients.3,9,10 It is thought that this novel therapy addresses the inflammation and 
oxidative stress placed on a body under septic conditions.8 The purpose of this literature review 
was to determine if adjunctive treatment with vitamin C improves patient outcomes in the 
management of sepsis. It was hypothesized that exogenous administration of vitamin C decreases 
mortality and complications in sepsis survivors. Objectives for this research include outlining the 
pathophysiologic effects of sepsis, current standards of care, the physiologic effects of vitamin C, 
and analysis of the clinical evidence of vitamin C alone and in combination with other agents as 
adjunctive therapy in septic patients. 
Background 
Pathophysiology of Sepsis 
 Sepsis begins as an isolated infection in the body that gains access to the bloodstream and 
spreads systemically. Previously, the devastating effects of sepsis were believed to be due to the 
a  , ,     a        a en 
is responsible for the effects seen.7 With the infection no longer isolated, the body responds with 
a dysregulated widespread inflammatory response via pro-inflammatory mediators.3 It is this 
systemic reaction to these mediators that induces the classic effects of sepsis on the body: 
hypotension, hemodynamic instability, poor tissue perfusion, and multi-organ dysfunction.8 
Ultimately, organs no longer receive adequate perfusion and become hypoxic, or lack oxygen 
delivery.11 Hypoxic tissues overproduce free radicals called reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) which cause oxidative stress throughout the cells in affected 
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tissues.3 The scavenging of free radicals performed by antioxidants is important to prevent 
damage to cellular components. When this process occurs systemically, extensive damage 
ensues. Left untreated, organ dysfunction develops, and eventual organ failure follows. As the 
disease state progresses, septic shock sets in.12 Even when providers follow standard treatment 
protocol, an unprecedented amount of these patients do not survive. Although there is some 
understanding to the pathophysiology of sepsis, this is a very complicated disease process, and 
further study of the mechanisms at play is necessary.3 
Current Standards of Sepsis Care 
 
Guidelines for the current management of sepsis were released by the SSC first in 2004 
with the most recent revisions having been released in 2016. As previously mentioned, this group 
of individuals have made it their mission to improve sepsis management and patient outcomes 
worldwide. The SSC has implemented standardized prot c  ca  b  a  c  a 
checklist of tasks to be completed for initial management of sepsis patients. These bundles were 
initially expected to be achieved within a 3-hour window from time of presentation. However, 
after studies strongly supported the use of these bundles, the SSC updated their guidelines in 
2018 to initiate bundle components within a 1-hour window.7 Tasks to be performed in this 1-
hour guideline include measuring serum lactate levels, administration of broad-spectrum 
antibiotics after blood cultures are obtained, and infusion of crystalloid fluids at 30 mL/kg if the 
patient is hypotensive with subsequent administration of vasopressors.13 These guidelines are 
used to initially manage septic patients regardless of whether they are presenting to the ED or are 
already in the ICU and have now developed sepsis. Based on interviews conducted with 
practicing physicians and physician assistants (PA-Cs) that have experience managing septic 
patients, the guidelines set forth by the SSC are standard operating procedure within numerous 
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health systems and departments within those health systems. One such interviewee is Meredith 
Wold, a hospitalist PA-C practicing at a large tertiary care hospital in St. Paul, MN, states that 
her practice follows the 1-hour bundle guidelines, and that patients coming in via the emergency 
department typically have the bundle initiated by ED staff. Another interviewee, Vanessa Bester, 
EdD, a PA-C and PA educator with experience caring for ICU patients amongst many other 
patient populations, expressed the use of the SSC guidelines as well during her time in the ICU. 
Shari Robbins, MD, the Sepsis Director for Emergency Care Physicians Northeast Division in 
Minnesota, also includes the bundle components in her initial work-up of septic patients 
presenting to the emergency department.  
Although not included in the 1-hour bundle, the SSC also recommends implementing 
source control measures as soon as possible after a diagnosis of sepsis or septic shock is made.2 
Source control involves defining the anatomic site of infection and providing subsequent 
interventions to control the infection at that site.2 A few examples of source control measures 
include the removal of an infected device, necrotic tissue debridement, and abscess drainage.2 
Eric Van Hecke, an emergency medicine PA-C, considers source identification an important part 
of his initial workup with septic patients presenting to the ED. Eric mentions that depending on 
the suspected source, the imaging and serum studies used in his initial workup of these patients 
varies. After initial workup and resuscitative efforts in the ED, these patients typically are 
admitted to the ICU, where subsequent management varies as lab results are obtained and are 
monitored for possible organ dysfunction and progressive organ failure. 
 Organ failure is believed to occur in 33.6% of septic patients, and of those that develop 
organ failure of three or more organs, 70% will not survive.14 Therefore, prognosis of a septic 
patient is largely dependent on organ dysfunction. It is for this reason that clinical scoring tools 
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were created to determine patient prognosis and the severity of organ dysfunction. There are 
multiple tools available, such as the Multiple Organ Dysfunction Score (MODS), however, the 
Sequential Organ Failure Assessment (SOFA) score (Table 1), is the most commonly used 
system in practice today.12,15 The SOFA score evaluates various body systems, which include the 
respiratory, hematologic, hepatic, cardiovascular, neurologic, and renal systems. The status of 
each system is scored individually from zero to four based on clinical and laboratory criteria, 
with higher scores indicating failure of that organ system, and thus a worse prognosis.15,16 Aside 
from the iatrogenic effects of sedatives on the neurological evaluation, the scoring system takes 
clinical interventions into account.12 Patients with a score that increases by two or more points 
from baseline are associated with an in-hospital mortality of 10%.12 Patients are assumed to have 
a baseline SOFA score of zero unless underlying organ dysfunction prior to infection is already 
known, a   c  ca  b   a   a  a a  a  c . The 
SOFA score has been validated in numerous studies as an effective clinical tool in assessing 
morbidity in the critically ill patient.17 
For out-of-hospital patients, such as those in the emergency department, a quick SOFA 
(qSOFA) score can be used to rapidly identify a poor prognosis in patients with a suspected 
infection. The clinical criteria used in qSOFA are respiratory rate greater than or equal to 22 per 
minute, altered mentation utilizing the Glasgow Coma Scale, and a systolic blood pressure less 
than or equal to 100 mmHg. The qSOFA requires no laboratory testing, as the tool includes only 
respiratory rate, mental status examination, and blood pressure.12 The concept driving the 
utilization of qSOFA is its ability to allow the clinician to promptly assess whether a patient 
requires further SOFA criteria workup and possible escalation of care or referral, which is 
typically indicated with a score of 2 or more.12 
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Physiologic Effects of Vitamin C 
 
 Although humans are incapable of synthesizing ascorbic acid, the vitamin plays a crucial 
role in various physiologic processes.18 Vitamin C is an antioxidant, meaning it prevents the 
oxidation of free radicals, such as ROS and RNS, by reducing them and protecting the cells from 
oxidative stress. Additionally, the vitamin works to improve microvascular perfusion and 
inactivate enzymes implicated in causing endothelial dysfunction and vascular compromise 
during septic states.8 
 Vitamin C also plays a role in the synthesis of vasopressors and catecholamines.5 
Antidiuretic Hormone (ADH), a vasopressor, prevents fluid loss in the kidneys and works 
against the development of hypotension. A role of catecholamines, such as epinephrine, is to 
increase arterial pressure and cardiac output when the body is under stress. ADH and 
catecholamine levels initially rise substantially in the septic patient, however, eventually deplete 
in these critically ill patients and hypotension ensues with subsequent shock.8 
 Finally, vitamin C is an important player in proper function of the immune system. 
Leukocytes have been found to have high levels of intracellular vitamin C, and studies show this 
facilitates chemotaxis, supports the proliferation of lymphocytes and causes oxidative destruction 
of bacteria.8 Furthermore, vitamin C has been shown to have bacteriostatic properties.3 Being 
that vitamin C is described as a vital component to physiologic roles throughout the body, it is no 
surprise that it is a frontrunner prospective treatment in current sepsis research. 
Vitamin C as a Solo Adjunctive Therapy 
 
 The physiologic understanding of vitamin C, along with its potential role in sepsis 
management, has garnered the attention and enthusiasm of the medical community. Additionally, 
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serum ascorbic acid levels have been documented as being deficient in critically ill patients, with 
participants in a study by Fowler et al. having baseline levels of 17.9 +/- 2.4 M (N = 50-70 M) 
at admission.9 For these reasons, numerous studies revolving around the vitamin being an 
adjunct intervention to standard sepsis management have been conducted. Research focusing on 
the use of vitamin C in septic patients utilize various measures to determine how exactly vitamin 
C may benefit this patient population, and often include these measures as primary or secondary 
outcomes in the study at hand. Measures typically included are patient hemodynamics, serum 
biomarker levels, SOFA scores, mortality rate, resource allocation, and adverse events. 
 As mentioned previously, a complication septic patients face is hypotension, and if severe 
enough, may precipitate septic shock. The blood pressure of these patients typically does not 
improve with the administration of intravenous fluids alone, and thus often require the use of 
vasopressor medications. According to the SSC, norepinephrine is the first-line vasopressor of 
choice in septic shock refractory to fluids.2 Therefore, norepinephrine is the drug of choice when 
 a  C  c      a   ca   c c . A meta-
analysis of two different studies demonstrated vitamin C significantly reduces the dose and 
duration of norepinephrine administered to patients undergoing septic shock.19 This meta-
analysis included a study by Zabet et al., c   a  C  c   a  
requirements in 28 septic shock patients, the results of which can be seen in Table 2.20 In this 
study, the mean dose of norepinephrine required was found to be less in the vitamin C treatment 
group than the control (7.44 +/- 3.65 vs. 13.79 +/- 6.48 mcg/min).20 Additionally, the time 
patients spent requiring norepinephrine was also found to be less in the treatment group (49.64 
+/- 25.67 vs. 71.57 +/- 1.60 hours).20  
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Several studies have observed the effects of vitamin C on biomarkers in septic patients. 
Various biomarkers are measured to indicate and follow the severity and course of sepsis. 
Elevated levels of these biomarkers suggest an increased mortality rate in septic patients.8 One 
study found a reduction in both procalcitonin and C-reactive protein biomarkers, and another 
found a reduction in two relatively new biomarkers, cell-free DNA (Figure 1) and mitochondrial 
DNA, with the administration of intravenous vitamin C in critically ill septic patients.9,21 C-
reactive protein and procalcitonin both serve as inflammatory biomarkers, meaning elevated 
levels indicate tissue inflammation in the body, a hallmark of sepsis. The cell-free DNA 
biomarker is exhibited when cells undergo necrosis or apoptosis and release DNA fragments into 
the serum, which accounts for the elevated levels seen in septic patients.21 The mitochondrial 
DNA biomarker measures mitochondrial nucleotides that serve to signal circulating neutrophils 
to the site of infection.21 Understanding the function of these biomarkers makes it apparent that 
elevated levels in a suspected sepsis patient are worrisome, so trending serum levels may be 
helpful in predicting patient outcomes and guiding resuscitative efforts. 
 The importance of clinical scoring tools in determining the prognosis of septic patients 
was mentioned previously, so it is to no surprise that these scores are measured and trended to 
a  a  C  cac  in clinical trials. One particular trial utilized high and low doses 
of ascorbic acid infusion, with the high dose infusion group showing a significant decrease in 
SOFA scores compared to placebo (Figure 2), which is suggestive of an improvement to these 
patie  a  c .9 Another study, a randomized controlled trial by Nathens et al., 
showed improvement in organ dysfunction scores in patients receiving antioxidant 
supplementation (which included vitamin C) compared to placebo.22 The study included 595 
critically ill patients and utilized the MODS score to determine the extent of organ dysfunction. 
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The antioxidant treatment group had multiple organ failure rates of 2.7% compared to 6.1% in 
the control group upon follow-up scoring.22  
One of the major patient outcomes recorded in the literature is the patient mortality rate. 
A diagnosis of sepsis carries a high yet variable mortality rate, with estimates ranging from 30-
50%, so any improvement in mortality would surely be welcomed.6,14 Vitamin C infusion 
appears to have beneficial effects on the body beyond the initial hospital stay, touting reduced 
mortality rates within a month from the treatment start date. The CITRIS-ALI randomized 
controlled trial by Fowler et al. showed a 28-day mortality rate of 46.3% in the placebo group, 
compared to 29.8% in the vitamin C treatment group.23 Another study showed even more 
impressive differences, with 28-day mortality rates for placebo versus treatment group of 64.28% 
and 14.28%, respectively.20  
Other patient outcomes often measured in the literature is that of resource allocation by 
means of time a patient spends in the ICU, on mechanical ventilation, and in the hospital. The 
study by Nathens et al. showed the intervention group to have a reduction in the time spent on a 
mechanical ventilator, the time spent in the ICU, and the overall length of hospital stay (0.9, 1.2, 
and 0.4 days less than the control group, respectively).22 The aforementioned CITRIS-ALI trial 
noted improved outcomes over the placebo group comprised of more days free of mechanical 
ventilation at day 28 (13.1 vs. 10.6), days free of the ICU at day 28 (10.7 vs. 7.7), and days free 
of being in the hospital at day 60 (22.6 vs. 15.5).23 A retrospective study of veteran ICU patients 
with sepsis by Mitchell et al. had mixed results. This study found a statistically significant 
improvement in length of ICU stay in the vitamin C treatment group compared to the control 
group (7.1 versus 15.6 days, respectively) however, there were no improvements to the overall 
length of the hospital stay.24 
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 Adverse events are a concern in any sort of medication or intervention, and vitamin C is 
not exempt from this. Hypernatremia is an adverse event researchers are concerned about 
developing in study participants receiving vitamin C infusion.9,11 Preparations of vitamin C 
infusions typically have a minor sodium load, and corticosteroids tend to cause sodium retention, 
so development of hypernatremia is an intuitive and reasonable concern with this intervention.9,25 
A randomized controlled trial utilizing combination therapy indicated the treatment group had a 
greater incidence of participants developing hypernatremia compared to the control group (13 vs. 
3, respectively).25  
Additionally, there is concern for the development of nephrolithiasis via formation of 
calcium oxalate kidney stones, particularly in those with renal failure being given high doses of 
vitamin C.10,14,18,26 High doses of vitamin C increases oxalate production, which crystallizes in 
dysfunctional kidneys to form kidney stones.10,16 However, a study by Padayatty et al. assessed 
the adverse events of high dose vitamin C administration in 9,328 patients. Out of the thousands 
of patients in this study, only three developed kidney stones (1 being calcium oxalate, 2 being 
unspecified).16 Although there is reason to be concerned for development of adverse events in 
the administration of vitamin C, numerous studies have reported little to no occurrence of these 
events.  
Vitamin C in Combination Therapy 
 
Recent novel approaches utilizing vitamin C in sepsis are going beyond its use as a sole 
additional intervention to current standards of care by additionally including a steroid (primarily 
hydrocortisone) and thiamine (Vitamin B1). This combination utilizes components that are 
affordable, readily available, relatively safe, and thought to work in conjunction with multiple 
overlapping pathways  b  a   b      and thus prevent 
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sequela such as organ failure and death.5,10 Taking the low-cost and accessibility of this 
combination into consideration, if a benefit in sepsis is proven, the burden of sepsis could be 
dramatically reduced around the world. 
 The addition of a corticosteroid is primarily due to its anti-inflammatory effects for shock 
control and acclaimed synergistic effects when paired with ascorbic acid.2,5 Corticosteroids work 
to attenuate inflammation via numerous mechanisms, but most significantly by repressing genes 
encoding for pro-inflammatory pathways.5 Corticosteroids are also thought to improve 
catecholamine function targeting vascular smooth muscle.27 Hydrocortisone was introduced into 
the SSC 2004 guidelines, and has remained the corticosteroid of choice through the latest 
guidelines released in 2016.2,27 Current standard of care recommends the addition of 
hydrocortisone in patients with shock refractory to fluids and vasopressor administration.16 
Tangible results of the effects of hydrocortisone have been reported in recent studies in 2018 on 
patients with septic shock.5 One of these is the ADRENAL study, a randomized controlled trial 
following 3,658 septic shock patients undergoing mechanical ventilation, which were separated 
into a hydrocortisone treatment group and placebo group.28 Although no statistically significant 
differences in 90-day all-cause mortality were found, those receiving hydrocortisone treatment 
came out of shock sooner (median duration 3 vs. 4 days), a finding that was deemed statistically 
significant.28 The other study, dubbed APROCCHSS, is a randomized controlled trial that 
utilized two corticosteroids, hydrocortisone combined with fludrocortisone, in septic shock 
patients. This study also found the treatment group to have more days free of vasopressors than 
the placebo group by day 28 (17 vs. 15).29 The findings from these studies, along with the 
recommendations put forth by the SSC, have provided a basis for the addition of corticosteroids 
to sepsis combination therapy.  
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 Patients with critical illnesses, such as sepsis, have progressively declining thiamine 
levels, and patients with a thiamine deficiency may have an increased risk of death due to this 
deficiency.10,11 Considering thiamine deficiency is not uncommon in patients that present with 
sepsis, it is intuitive to hypothesize that thiamine supplementation could prove beneficial to these 
patients.11 In addition to having some anti-inflammatory effects, thiamine has many functions 
throughout the body where it acts to reduce oxidative stress and also plays a role in proper brain 
function via nerve tissue repair, neuronal communication, serotonin uptake, and myelin sheath 
synthesis.5 Thiamine has been implicated in causing less oxalate to form from the metabolism of 
vitamin C, which helps to prevent calcium oxalate stones from forming in the kidneys.4,14,16 
Further, thiamine deficiency is believed to be a cause of elevated serum lactate levels.11,16 
Elevated serum lactate is not exclusive to sepsis, but is often seen in sepsis and was a common 
laboratory finding in septic patients amongst the studies reviewed.5,10,11,24,29,30 Serum lactate is 
used as a marker for tissue perfusion, with elevated levels indicating hypoperfusion, so serially 
measuring lactate can help guide resuscitative efforts.13 The effects of thiamine in septic shock 
have been studied; treatment groups exhibited significantly reduced 24-hour serum lactate levels, 
were less likely to need renal replacement therapy, and had improved 30 day mortality outcomes 
compared to placebo.5 Since septic patients are often deficient in thiamine and turnaround time 
for tests on serum levels takes a few days, including thiamine as part of the early treatment 
initiation bundle for sepsis may be of benefit.16 No major adverse effects have been documented 
with administration of thiamine, and considering its affordability, supplementation in sepsis 
patients could make this a low-risk yet high-reward addition to combination sepsis therapy.11 
 Current research suggests the combination of ascorbic acid, thiamine, and steroids (ATS) 
shows promise in being an effective addition to sepsis management. In a retrospective before and 
Vitamin C and Sepsis 16 
 
after study by Marik et al., 47 patients were followed in each arm of the study. The treatment 
group was reported as having an in-hospital mortality rate of 8.5%, compared to the placebo 
group with a rate of 40.4%.10 The benefits of ATS did not end there, however. In comparison to 
the control group, the treatment group also exhibited a rapid reduction in procalcitonin levels 
(median clearance 86.4% vs. 33.9%) and change in SOFA scores (4.8 +/- 2.4 vs. 0.9 +/-2.7) with 
zero participants in this group developing progressive organ failure.10 The treatment group also 
spent less time requiring the use of vasopressors than the control group (Figure 3).10 On the other 
hand, the control group in this study saw relatively no improvement in procalcitonin levels, and 
those that survived were slow to see improvements to their SOFA scores.10  
Another study, called the ORANGES trial, was completed in June 2019 by Iglesias et al. 
in which ATS was used as an intervention in 137 septic and septic shock patients. This was a 
double-blind randomized controlled trial that showed patients in the intervention group 
exhibiting a statistically significant improvement in shock recovery time compared to the 
placebo group.26 This outcome could normally be questioned as a result of the use of 
corticosteroids, however, the team realized this and adjusted for corticosteroid use, meaning ATS 
combination therapy was in fact found to decrease the amount of time patients were using 
vasopressors from 54 hours in the control group to 34 hours in the treatment group.26 The 
ORANGES trial, however, found no statistically significant secondary outcomes, which included 
SOFA scores, mortality, ventilator-free days, and procalcitonin biomarkers.26 
One last study, a randomized controlled trial, found the beneficial effects of combination 
therapy to be greatest in those that started combination therapy within 48 hours of diagnosis. 
This study took place in a tertiary academic hospital in China that enrolled patients in various 
stages of sepsis. The prespecified 48-hour patient subgroup exhibited 28-day mortality rates 
Vitamin C and Sepsis 17 
 
superior to the control group (13.6% vs. 47.6%).25 Procalcitonin clearance rates at the 72-hour 
mark were also greater in this subgroup (75.6% vs. 58.9%).25 Other outcomes that were 
improved in this subgroup but not considered statistically significant included less time spent in 
the ICU, less time on vasopressors, 72-hour lactate clearance rate, and 72-hour change in SOFA 
scores.25 
Despite several studies claiming benefit to using vitamin C in the management of septic 
patients, alone or in ATS combination therapy, other studies conclude otherwise. A randomized 
controlled trial looking at vitamin C alone by Fowler et al. concluded that there are no 
statistically significant differences between vitamin C and placebo regarding reduction in SOFA 
scores and inflammatory markers.23 The VITAMINS trial, conducted by Fujii et al., has also 
documented results that clash with the purported benefits of vitamin C. The VITAMINS 
randomized controlled trial utilized ATS combination therapy and found no difference between 
groups in time alive, duration of septic shock, or all-cause mortality at 28 days, among various 
other secondary outcomes.30 A final study, this one being retrospective, also concluded no 
statistically significant differences in outcomes between the ATS treatment group and the 
standard care group.27 Outcomes measured in this study were hospital and ICU mortality, 
hospital and ICU length of stay, and requirements for vasopressors and renal replacement 
therapy.27 
 Conflicting evidence amongst studies demonstrates a need for further research regarding 
the effects of vitamin C in sepsis. Acc    U.S. Na a  L b a   M c  
ClinicalTrials.gov website, there are currently over a dozen randomized controlled trials 
recruiting participants to further investigate the potential role of vitamin C in sepsis and septic 
shock, either alone or in combination therapy. There are numerous other trials awaiting to 
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publish results. One such study is the LOVIT (Lessening Organ dysfunction with VITamin C) 
Trial, which began recruiting participants (with a goal of up to 800) for the study in November 
2018 and is scheduled to conclude in November 2021. The LOVIT Trial is a phase III 
a  c  a  a  ac     25 ICU   a  c   
determine superiority of vitamin C as an isolated adjunct intervention in septic patients to reduce 
mortality compared to placebo.31 Another trial that just completed in January 2020 is the Vitamin 
C, Thiamine and Steroids in Sepsis (VICTAS) study, which enrolled 501 participants into its 
phase III, multicenter, double-blind, randomized controlled trial.4 Once published, the results of 
each of these studies, amongst the many others in progress, with their larger sample size and 
well-   ,   a ab    ATS c b a  a  
currently unclear role in sepsis management. 
Methods 
The electronic database PubMed was used to search literature that addressed the research 
. K      a c   V a  C , A c b c Ac , S , 
P , P -S , SOFA Sc , C ca , a  I  Ca  U . The 
literature search was completed between June 1st and July 12th, 2020. Search results yielded peer-
reviewed articles filtered within the past 10 years, with the majority of articles used being 
published within the last 5 years. O  c     a    a c  The 
SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure  by 
Vincent et al., as it provides the definition of the SOFA score, which was created in 1994. One 
 ab  c    2002 a c  b  Na   a .  Ra , c  a  
 a a  a   c ca   ca  a , c  a     a  
studies testing vitamin C, amongst other antioxidants, in critically ill patients. In addition, 
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relevant studies cited within the peer-reviewed articles from the search results were identified 
from the references list and reviewed. Utilization of the references list in the initial articles 
reviewed was done for multiple reasons, the first being to find additional studies for use in the 
literature review. Reviewing the sources of each article used in this review also prevented 
overreporting of the same study results cited in two or more articles. Finally, reviewing original 
studies allowed for a personal analysis of that study to verify accuracy of reported results. For 
articles in which the full text versions could not be obtained from PubMed, Augsburg 
U  b a  a   a  . Finally, expert interviews were conducted 
with practicing physicians and physician assistants that have experience caring for septic 
patients. The goal of the interviews was to learn more about current sepsis management and to 
     a  C   a  a  a   a     ac c . 
Potential interviewees were contacted via email, and the providers interested in participating 
were sent a follow-up email with the six interview questions as shown in Table 3. Participants 
were asked to consider reaching out to colleagues known to manage septic patients that may 
have interest in completing the interview questions. 
Discussion 
Sepsis, a life-threatening inflammatory disease process, has ravaged intensive care units 
worldwide. With staggering mortality and rehospitalization rates, paired with the serious 
complications of post-sepsis syndrome, sepsis dominates as one of the most expensive hospital 
stays a person could experience.2-6,14,26,32 Current standard of care protocols and early treatment 
bundles recommended by the Surviving Sepsis Campaign have reduced the mortality rate and 
improved patient outcomes substantially, however, despite the improvements, the mortality rate 
continues to range between 20-35% and as high as 50% in those that present with septic 
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shock.3,8,26 For these reasons an effective treatment for sepsis is so desperately needed, which has 
led to many potential therapies being tested over the years.3,5,8,16,27 Vitamin C is among one of 
the newest prospective treatments, and promising results from early studies have garnered much 
attention from the medical community. Vitamin C has been studied both as a solo adjunct to 
current standard of care sepsis protocols in addition to a more recently proposed triple therapy 
with a corticosteroid (namely hydrocortisone) and thiamine (vitamin B1). This combination has 
been tested in a few studies already, with many more in progress or currently awaiting results 
and publishing. Some providers, particularly in the ICU, have already adopted its use in practice. 
Ryan MacDougall, an internal medicine MD at Delaware County Memorial Hospital in 
Pennsylvania, frequently manages septic patients. In his response to the interview questions, he 
said that when using vitamin C in septic patients, he has only ever used it in combination with 
corticosteroids and thiamine. Doctor MacDougall mentions that some providers opt to use 
vitamin C without the remaining triple therapy components, however, he has seen good patient 
outcomes with triple therapy administration within 12 hours of admission. The components in 
this proposed triple therapy are thought to work synergistically with each other in attenuating the 
pathophysiologic process of sepsis and septic shock.5,14,16 
Understanding the physiology of vitamin C, hydrocortisone and thiamine in the body 
provides a sound basis for the plausible use of each of these interventions in attenuating the 
complex, not yet fully elucidated pathophysiology behind a septic disease state. Critically ill 
patients, such as those that are in a septic state, are documented to have deficient levels of 
vitamin C.3,9,10,20 Exogenous administration of vitamin C resolves the deficiency in these 
patients. Doses used in the literature were typically split into divided doses every 6 hours and 
found to range from 50 mg/kg/day on the low end to 200 mg/kg/day on the high end.9,20,22,23,31 
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Significant improvement or normalization of serum levels of vitamin C was seen within 12 to 24 
hours after initiation, whereas serum levels in the control or placebo groups continued to trend 
downward.9,20,22,23 Researchers opting for combination therapy have consistently reported the 
addition of 50 mg hydrocortisone every 6 hours and 200 mg thiamine every 12 hours.4,10,14,24-27,30 
The improvement in serum levels of vitamin C amongst the intervention groups then begs the 
question: did those treated with vitamin C with or without hydrocortisone and thiamine have 
improved outcomes over the placebo or control groups? Researchers attempt to answer this 
 b  a  a  c , c  a  a c , rum 
biomarker levels, SOFA scores, mortality rate, resource allocation and adverse events.  
Due to various pathophysiologic processes, septic patients are prone to becoming 
hemodynamically unstable, meaning their blood pressure drops, and patients are deemed 
hypotensive at a blood pressure of 90/60. Intravenous fluids are given as first-line management 
to improve blood pressure, however, is often not enough to correct the hypotension.2,20 At this 
point, vasopressors are given, with norepinephrine being the recommended first-line agent.2,20 As 
the hypotension progresses, septic patients are defined as being in septic shock if vasopressors 
are required to maintain a mean arterial pressure (MAP) greater than 65 mmHg with a serum 
ac a    2 /L, a  hypovolemia has been excluded as an underlying cause.12 Various 
 a   a  a  C  c     c   c c , ca  
b  a  a    a . Vitamin C has been shown to reduce the dose of 
vasopressors required by patients to maintain an adequate mean arterial pressure.20 In addition to 
reducing required doses, vitamin C appears to decrease the duration septic patients require 
vasopressors.19,20 There is evidence that combination therapy also helps to improve patient 
hemodynamics, primarily in the time to shock resolution.10,25,26 The idea behind this mechanism 
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is the hydrocortisone working in unison with the vitamin C by improving  a  uptake 
into cells.16 Additionally, hydrocortisone works to decrease inflammation, improve 
catecholamine function, and increase serum volume via sodium and water retention, all of which 
 ab  a a  b  .2,5,16,27-29 During her interview, Doctor Robbins agreed 
that although she has not utilized vitamin C or its combination therapy agents in unison within 
the emergency department, steroids are occasionally used while managing shock patients and are 
started with the second administration of vasopressors. These findings, along with the extensive 
prior research on hydrocortisone, support the potential for vitamin C and combination therapy to 
improve hemodynamic stability among septic patients. 
 Research into biomarkers involved with sepsis is becoming more and more prevalent. 
Procalcitonin and C-reactive protein are biomarkers that have been well-established as being 
elevated in sepsis, with procalcitonin being trended most commonly throughout the literature. 
Research suggests exogenous administration of vitamin C reduces procalcitonin and C-reactive 
protein in septic patients.9 These findings have been echoed in some studies on ATS combination 
therapy, where a prompt reduction in procalcitonin levels occurred in the intervention group, but 
did not occur in the control groups.10,25 However, this conclusion was not supported in several 
studies reviewed, one employing vitamin C alone and the other employing combination 
therapy.23,26 The administration of ascorbic acid causing an overall downward trend in serum 
levels of these biomarkers builds upon ascorbic acid being a promising adjunct treatment to 
sepsis. Research into novel biomarkers is ongoing as two more, known as cell-free DNA and 
mitochondrial DNA, were recently implicated in being elevated in sepsis and showing 
subsequent attenuation in serum levels with vitamin C administration.21 Further evidence 
defining the efficacy of new and old biomarkers alike, along with their responses to vitamin C 
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administration, is much anticipated. It is important to note that the use of biomarkers should 
always be looked at in conjunction with the clinical picture, as these tests are not perfectly 
sensitive nor specific. For example, a septic patient that has significantly improved clinically yet 
has an elevated serum procalcitonin should not be immediately deemed as having a poor 
prognosis. An example of this point being used in practice was identified by Meredith Wold, PA-
C. During the interview, Meredith mentioned that a mildly elevated lactate is not necessarily bad, 
and that aggressively trying to normalize that lactate level with IV fluids may in fact be worse 
for the patient. 
Once organ dysfunction occurs, a patient is said to have severe sepsis.12 The extent of 
organ dysfunction is readily estimated via the SOFA score, c  a  c a    1990  a  a 
tool to identify mortality risk in ICU patients but is now commonly used in the diagnosis of 
sepsis.17 A patient must have an increase in SOFA score by two or more points to be considered 
to have organ dysfunction.12 As the score increases, the associated mortality rate also 
increases.12,15,17 Its use also extends to monitoring patient improvement, particularly in the many 
clinical trials taking place to find adjunct treatments for sepsis.17 Therefore, quantification of 
organ dysfunction is often done in clinical trials to assess whether an intervention is capable of 
reducing the organ dysfunction at hand. SOFA scores are typically obtained at baseline in studies 
and then participants are scored again at prespecified time intervals. Intervention and control 
groups are shown to have similar SOFA scores at baseline upon hospital admission and study 
enrollment.9,10,20,22-27,33 This helps to ensure quality in the conclusions made based on any 
differences found between groups thereafter. Despite one study finding no improvement, vitamin 
C as a solo adjunctive sepsis therapy appears to improve SOFA scores in septic patients 
compared to control and placebo groups.9,22,23 Research focused on combination therapy boasts 
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similar findings. Again, one study found no significant differences, however, studies as a whole 
report SOFA scores are improved in patients receiving vitamin C, hydrocortisone, and thiamine 
in conjunction.10,25 The literature currently available favors vitamin C and ATS combination 
therapy as being capable of reducing organ dysfunction, a finding that supports its use in septic 
patients. 
Of course, a major primary outcome that research on vitamin C is centered around is that 
of patient mortality. Given the intimidating mortality rate associated with a sepsis diagnosis, it is 
imperative further interventions capable of reducing this burden are discovered.6,14 Current 
studies indicate improvements in 28-day mortality rates when vitamin C is used in addition to 
standard treatment.20,23 One of the randomized controlled trials published found no difference 
between groups in mortality rates, however.30 Adding hydrocortisone and thiamine into the 
vitamin C intervention group appears to lessen mortality rates as well, however, one study 
claimed this finding was not considered statistically significant.10,25,26 Although a reduction in 
mortality rate has not been a unanimous finding in each of the studies published, it is important 
to note that none of the studies reviewed found a statistically significant increase in mortality rate 
in those receiving vitamin C or combination therapy. 
Currently, results vary on whether vitamin C lessens the time spent using hospital 
resources. The resources consistently documented throughout the literature include time spent in 
the ICU, hospital, and on mechanical ventilation. Overall, conclusions on the use of hospital 
resources are variable. Reduction in the time spent utilizing these resources is supported by 
various studies.22-24 On the other hand, several other studies report there being no superiority in 
length of ICU or hospital stay in treatment groups, a finding noted in both vitamin C and 
combination therapy interventions.20,27,30 Septic patients face extraordinary hospital costs, so any 
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improvement in lessening resources required to manage these patients, no matter how minute, 
will lessen the financial burden on patients and hospitals alike. Less time utilizing hospital 
resources also frees up mechanical ventilators and creates more room in the ICU and general 
wards for other patients in need of these resources. 
There is always a risk to using any designated intervention in patient care. In the case 
with vitamin C infusion, the literature consistently agrees there are two of primary concern: 
hypernatremia and calcium oxalate nephrolithiasis. There is a sound physiologic basis for these 
concerns. Vitamin C infusion preparations have an additional sodium load, so when coupled with 
the sodium from intravenous fluids and the sodium retentive effects of hydrocortisone, 
hypernatremia may very well develop.9,11,25 Kidney stone formation is also an established 
complication with excessive vitamin C.10,14,18,26 This is particularly evident in those with renal 
dysfunction, which is not an uncommon finding in septic patients. Despite legitimate concerns 
for the development of these adverse events, an overwhelming amount of the studies conducted 
thus far have failed to show adverse events in critically ill patients due to vitamin C infusion, and 
it would appear the potential benefit outweighs the potential risk.9,10,14,16,20,22-24,26,30  
Several implications exist with applying vitamin C therapy to the standard protocol of 
sepsis management. If vitamin C therapy is concluded to be ineffective in providing benefit to 
septic patients, there will be disheartening effects induced by the failure of yet another novel 
sepsis therapy. Further, implementing a therapy that lacks definitive patient benefit, no matter 
how affordable, would increase the already insurmountable costs associated with sepsis, correct? 
As it turns out, implementing vitamin C combination therapy may in fact save money. A cost-
analysis was performed by Blythe et al. to determine the economic impact if the treatment bundle 
proposed in the study by Marik et al. were to be implemented before more definitive studies are 
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finished.32 The cost-analysis took into consideration expected costs from the available literature 
and spanned the analysis over five years to account for long-term impact. Three scenarios were 
used in the analysis to model the intervention as being either effective as described in the Marik 
et al. study, less effective than described, and ineffective. The analysis found that implementing 
vitamin C combination therapy, even in the less effective scenario, would save the United States 
billions of dollars and millions of life-years.32 This analysis was completed in 2017, so 
considering that the studies completed since then overall provide further support for 
implementing this intervention, it can be anticipated that the benefits to costs and lives as 
described are still applicable today.  
However, health systems must consider the risks of implementing new treatment 
standards that may have to be rescinded if the more recent trials soon to be published have 
evidence largely against the use of vitamin C in sepsis. For these reasons, the use of vitamin C 
and its combination therapy has not been widely adopted into everyday practice, particularly in 
academic medical centers bound by organizational protocols. This sentiment was echoed during 
the interview with Doctor Bester, who noted a  a ground-breaking study or new published 
guidelines  a  ca    c a  ac c     -based setting unless a 
clinical trial that involves a specific treatment (i.e. vitamin C) is in progress at that medical 
center. 
There are limitations to the studies done thus far that make drawing conclusions difficult. 
One key conclusion that was practically unanimous throughout each article of the literature 
review is that studies with larger, multi-center populations and well-defined protocol need to be 
done before routine utilization of vitamin C (or ATS combination therapy) in sepsis management 
is considered. As of writing, the studies published have utilized small population sizes, making it 
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difficult to draw any conclusions with extreme certainty. Regarding combination therapy, there 
are numerous articles defining the physiologic basis of using vitamin C, hydrocortisone, and 
thiamine in conjunction, yet only a few completed studies that have tested this intervention in 
clinical trials. A few of the studies published are retrospective trials, so an emphasis on the need 
for prospective trials is warranted. Fortunately, initial results have sparked widespread interest 
and enthusiasm for the use of vitamin C in sepsis management, so research into this novel 
therapy is ongoing. 
Another important point worth noting is that one must exercise caution when drawing 
conclusions on individual components in combination therapy trials, as the effects of each 
individual component are at risk of being confounded by the others. This is particularly true with 
hydrocortisone in ATS combination therapy, as hydrocortisone has already been well 
documented to reduce the time patients require vasopressors in septic shock.33 The issue 
presented in this example is that the efficacy of combination therapy to reduce vasopressor 
requirements could be overestimated, when perhaps hydrocortisone alone would have been just 
as effective. Careful study design and interpretation is necessary to help mitigate these effects. 
Conclusion 
 Despite having such prevalence throughout the world, public awareness of sepsis is 
inadequate. Even providers may find it difficult to identify sepsis, as it can have a multitude of 
presentations given its systemic manifestations. Improved outcomes are associated with early 
identification and initiation of treatment. Ensuring clinicians are well-versed in the definitions 
and how to promptly recognize sepsis is the first step to reducing the associated global burden. 
Fortunately, groups such as the Surviving Sepsis Campaign and the Sepsis-3 Task Force have 
taken it upon themselves to define what constitutes sepsis and are continuing to improve upon its 
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management recommendations. The use of these recommendations has become and remains the 
standard protocol for sepsis management, which was a consistent response in the healthcare 
provider interviews conducted. For patients that survive an encounter with sepsis, it is imperative 
that their healthcare team prepare them for a possible change in quality of life, namely due to 
post-sepsis syndrome, re-hospitalization risks, and financial consequences.  
In agreement with the hypothesis, analysis of the literature review suggests the addition 
of vitamin C to standard sepsis therapy has beneficial patient outcomes. The potential benefits 
and relative affordability of vitamin C seem to outweigh the limited risk of adverse effects and 
the potential risk of no actual benefit. Despite the promising results from initial findings, until 
more c c   a  b , a  C   a  a  a c  a    
remains uncertain and experimental before widespread implementation into practice is adopted. 
This is supported by the fact that the majority of the providers interviewed have yet to utilize 
vitamin C in their management of septic patients. Numerous studies are underway to better 
determine the efficacy of both vitamin C and its combination therapy adjuncts. A 
recommendation for future studies is to determine the presence of any discrepancies between 
early administration and late administration of vitamin C (and combination therapy) relative to 
sepsis onset to establish a timeline distinguishing when this therapy is most effective. In the 
meantime, as vitamin C and other adjunctive therapies are explored, providers must utilize the 
strategies known to improve patient outcomes: hemodynamic stabilization, early administration 
of broad-spectrum antibiotics, and source control measures. 
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Appendices 
Table 1: SOFA Score Components15 
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Table 3: Questions Utilized in Expert Interviews 
1) Have you managed septic and/or septic shock patients in your practice before? 
 
2) What is included in your workup?  
 
3) What is considered routine standard therapy in your practice? 
 
4) Have you ever utilized vitamin C as an adjunct treatment in the management of sepsis? If so, was 
this initiated early in treatment or not until later in patients when standard therapy was not improving 
he pa ien  a ? Do o  recall he pa ien  o come ? 
 
5) Have you ever utilized combination therapy of vitamin C, hydrocortisone, and thiamine in the 
treatment of sepsis? If so, was this initiated early in treatment or not until later in patients when 
andard herap  a  no  impro ing he pa ien  a ? Do o  recall he pa ien  o come ? 
 
6) Any other experience you would like to share that was not covered in one of the previous questions? 
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